CN1218665A - High efficiency mifepristone preparation and its preparing method and use - Google Patents
High efficiency mifepristone preparation and its preparing method and use Download PDFInfo
- Publication number
- CN1218665A CN1218665A CN 97126039 CN97126039A CN1218665A CN 1218665 A CN1218665 A CN 1218665A CN 97126039 CN97126039 CN 97126039 CN 97126039 A CN97126039 A CN 97126039A CN 1218665 A CN1218665 A CN 1218665A
- Authority
- CN
- China
- Prior art keywords
- mifepristone
- surfactant
- pharmaceutically acceptable
- preparation
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 title claims abstract description 66
- 229960003248 mifepristone Drugs 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 11
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 16
- 230000035935 pregnancy Effects 0.000 claims abstract description 15
- 239000002563 ionic surfactant Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 7
- 230000000996 additive effect Effects 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 6
- 239000008180 pharmaceutical surfactant Substances 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 3
- 201000009273 Endometriosis Diseases 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 12
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000007962 solid dispersion Substances 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- 229960003511 macrogol Drugs 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 229920001400 block copolymer Polymers 0.000 claims description 5
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical group [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- -1 sodium alkyl sulfonates Chemical class 0.000 claims description 4
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 208000015994 miscarriage Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
- 208000000995 spontaneous abortion Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 206010000210 abortion Diseases 0.000 abstract 1
- 231100000176 abortion Toxicity 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 229940123788 Progesterone receptor antagonist Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000708 anti-progestin effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The mifepristone preparation consists of basically mifepristone, pharmaceutically acceptable surfactant and medicinal additive, and the said surfactant is selected from non-ionic surfactant and ionic surfactant. The present invention also relates to the preparation process of the said preparation and its application in preparing medicine for resisting early-stage pregnancy abortion and medicine for emergency contraception and medicine for curing uterine, endometriosis, breastcancer and other gynopathy. The preparation has the advantages of high biological utilization and reduced side effect, and its preparation process is simple and convenient.
Description
The present invention relates to mifepristone preparation a kind of novelty, that bioavailability is high, the preparation method and its usage of said preparation.
The chemistry of mifepristone (Ru 486) is by name: 11 β-(4-dimethylamino-phenyl)-17 beta-hydroxyl-17 alphas-propinyl-4,9-diene-3-ketone group-oestrane, be the very strong progesterone receptor antagonists of a kind of biological activity, be widely used as the medicine of antiearly pregnancy at present clinically.But because of its poorly water-soluble, so bioavailability only is about 50%; In addition, mifepristone demonstrates in animal experiment except that stronger antiprogestin effect is arranged, and the active side effect of certain Antiglucocorticoid is still arranged.These problems have caused certain difficulty all for the use of mifepristone.Therefore, for a long time, the personnel of this technical field wish to occur the mifepristone preparation of the novelty that bioavailability increases always, can improve the absorption of human body to active component in the mifepristone preparation like this, thereby can reduce the dosage of mifepristone clinically, reduce bad side reaction.
An object of the present invention is to provide the mifepristone preparation of the novelty that a kind of bioavailability increases, bad side reaction reduces.
Another object of the present invention provides the preparation method of described mifepristone preparation.
A further object of the present invention provides described mifepristone preparation at preparation antiearly pregnancy miscarriage medicine and treat purposes in the medicine of some gynaecopathia.
Purpose of the present invention realizes by such design: a kind of mifepristone preparation, basically by mifepristone and pharmaceutically acceptable surfactant, and medical additive is formed.Described pharmaceutically acceptable surfactant is selected from the surfactant and the ionic surfactant of nonionic.The amount ratio of mifepristone and ionic surfactant is 1: 0.05-1: 5 by weight; The amount ratio of mifepristone and nonionic surfactant is 1: 0.5-1: 20 by weight.In described mifepristone preparation, mifepristone can be respectively with nonionic surfactant, ionic surfactant or have nonionic surfactant concurrently and the material compatibility of ionic surfactant.
Nonionic surfactant used in the present invention is selected from such as Macrogol 2000-20000 with such as the pharmaceutically acceptable nonionic surfactant of polyox-yethylene-polyoxypropylene block copolymer (its molecular weight is 1000-9900, and the content of oxireme is 10-90wt%).
Ionic surfactant used in the present invention is selected from the pharmaceutically acceptable ionic surfactant of sodium lauryl sulphate, sodium cholate, eight sodium alkyl sulfonates and bromo geramine.
In optimized technical scheme of the present invention, the weight ratio of mifepristone and Macrogol 4000 is 1: 1-1: 5; The weight ratio of mifepristone and sodium lauryl sulphate is 1: 0.1-1: 1.5.
Described medical additive is the known conventional additives of this technical field, as soluble starch, crospolyvinylpyrrolidone, carboxymethyl starch sodium, hydroxypropyl emthylcellulose, magnesium stearate, microcrystalline Cellulose, ethanol etc., can select according to prior aries such as pharmacopeia and documents by the personnel of this technical field.
Described mifepristone preparation can be dosage forms such as tablet, capsule, granule.
The preparation method of mifepristone preparation of the present invention comprises:
A). make the solid dispersion of mifepristone by following three kinds of methods:
Be 1 with pharmaceutically acceptable nonionic surfactant with weight ratio with mifepristone ⅰ): 0.5-1: 20 amount is mixed, heating and melting; Or
Be 1 with pharmaceutically acceptable nonionic surfactant with weight ratio with mifepristone ⅱ): 0.5-1: 20 amount is mixed back solubilizer dissolving, evaporating solvent as for, described solvent can be the known any solvent that can dissolve above-mentioned component of this technical field personnel, as ethanol, dichloromethane etc.; Or
Be 1 with pharmaceutically acceptable nonionic surfactant with weight ratio with mifepristone ⅲ): 0.5-1: 20 amount is mixed, is ground to and melts;
Perhaps
B). with weight ratio is 1: 0.05-1: 5 measure the ethanol that mifepristone and pharmaceutically acceptable ionic surfactant are dissolved in meltage; And
C). when needing, steps A) and/or step B) material that makes mixes with medical additive, granulate with the method for routine.
The granule of gained can be made dosage forms such as tablet, capsule, granule by the technology of routine.
Mifepristone preparation of the present invention can be used for preparing the medicine that antiearly pregnancy is miscarried medicine, emergency contraception and treated some gynaecopathia, and described gynaecopathia comprises hysteromyoma, endometriosis, breast carcinoma etc.
Below in conjunction with specific embodiment the present invention is done further detailed elaboration, but the present invention is not limited by the embodiment of these narration usefulness.
Embodiment 1
2 milligrams of 10 milligrams of magnesium stearate of 12 milligrams of carboxymethyl starch sodium of 16 milligrams of crospolyvinylpyrrolidone of 60 milligrams of soluble starches of 75 milligrams of lactose of 25 milligrams of Macrogol 4000s of pharmaceutical formulation mifepristone
With 75 milligrams of Macrogol 4000 heating and meltingizations, add 25 milligrams of mifepristones, make solid dispersion after the cooling rapidly.Then, solid dispersion is mixed with 60 milligrams of lactose, 16 milligrams of soluble starches, 12 milligrams of crospolyvinylpyrrolidone, 10 milligrams of carboxymethyl starch sodium and 2 milligrams of magnesium stearate, granulate, sieve and drying.Tabletting is made tablet.
Embodiment 2
Pharmaceutical formulation (is example with 1000 slice, thin pieces)
Mifepristone 25 grams
Sodium lauryl sulphate 2.5 grams
Lactose 31 grams
Starch 12 grams
Polyvinylpyrrolidone K30 4 grams
50% ethanol is an amount of
Crospolyvinylpyrrolidone 4.8 grams
Magnesium stearate 0.7 gram
25 grammeter mifepristones and 2.5 gram sodium lauryl sulphates are dissolved in an amount of 50% ethanol, add 31 gram lactose, 12 gram starch, 4 gram polyvinylpyrrolidone K30,4.8 gram crospolyvinylpyrrolidone and 0.7 gram magnesium stearate, granulate through wet grain method, tabletting obtains required tablet.
Embodiment 3
According to embodiment 1 described method, but replace 75 milligrams of Macrogol 4000s to make required mifepristone preparation with 12.5 milligrams of Polyethylene Glycol 8000.
Embodiment 4
Press embodiment 1 described method, but replace 75 milligrams of Macrogol 4000s to prepare required mifepristone preparation with the polyox-yethylene-polyoxypropylene block copolymer that 500 millimole amounts are 1000, oxireme content is 90wt%.
Embodiment 5
According to embodiment 2 described methods, but replace 2.5 gram sodium lauryl sulphates to prepare required mifepristone preparation with 1.25 grams, eight sodium alkyl sulfonates.
Embodiment 6
According to embodiment 2 described methods, but replace 2.5 gram sodium lauryl sulphates to prepare required mifepristone preparation with 5.0 gram bromo geramines.
Embodiment 7
Pharmaceutical formulation
25 milligrams of mifepristones
150 milligrams of Macrogol 4000s
30 milligrams of lactose
60 milligrams of microcrystalline Cellulose
25 milligrams of mifepristones are mixed with 100 milligrams of Macrogol 4000s, add proper amount of acetone and make the mixture dissolving, boil off solvent and obtain solid dispersion.Then, solid dispersion is mixed with 60 milligrams of lactose, 30 milligrams of microcrystalline Cellulose, granulate, sieve and drying.Fill in the people 2# hard capsule.
Embodiment 8
75 milligrams of 25 milligrams of polyox-yethylene-polyoxypropylene block copolymers of pharmaceutical formulation mifepristone (Mw=7500,60 milligrams of 30 milligrams of microcrystalline Cellulose of lactose of oxireme content=80wt%)
25 milligrams of mifepristones are mixed with 750 milligrams of polyox-yethylene-polyoxypropylene block copolymers, and grinding obtains solid dispersion after disperseing.Then, solid dispersion is mixed with 60 milligrams of lactose, 30 milligrams of microcrystalline Cellulose, granulate, sieve and drying.Fill people 2
#In the hard capsule.
The test I: mifepristone preparation of the present invention is to the effect of rat anti early pregnancy
Getting body weight is that the sexual maturity of 180-200 gram, the SD rat of unpregnancy (Sino-British joint SIPPR-BK experimental animal company limited supply) are that the male rat that 280-300 restrains mates with body weight, make vaginal smear every morning, find sperm work gestation the 1st day, carry out gastric infusion at the 7-9 days dosage according to following table 1 and 2 and reach 3 days, the result is also shown in following table 1 and 2:
Table 1 mifepristone, mifepristone+sodium lauryl sulphate
Effect to the rat anti early pregnancy
| Group dosage (mg/kg) animal pregnancy number/total number of animals of pregnancy rate % litter size |
| Contrast-10,/10 100 11.6+1.7 |
| Mifepristone 2.8 5,/10 50 5.7 ± 5.9 |
| Mifepristone+2.8 0/1 00 **Lauryl sulphate acid 2.8 sodium |
| Lauryl sulphate acid 2.8 10,/10 100 10.9 ± 0.1 δ sodium |
Table 2 mifepristone, mifepristone+Macrogol 4000
Effect to the rat anti early pregnancy
| Group dosage (mg/kg) animal pregnancy number/total number of animals of pregnancy rate % litter size |
| Contrast-10,/10 100 11.2+1.5 |
| Mifepristone 2.8 5,/10 50 5.9+5.6 |
| Mifepristone+2.8 2,/10 20 1.6 ± 2.9 lauryl sulphate acid, 8.4 sodium |
| Lauryl sulphate acid 2.8 10,/10 100 11.0+1.7 **Sodium |
*P＜0.01 compared with the control.
From above-mentioned result of the test as seen, compare with independent use mifepristone, mifepristone preparation of the present invention obviously increases the antiearly pregnancy effect of animal, uses surfactant not have the antiearly pregnancy effect separately.
Mifepristone preparation of the present invention has the advantage of bioavailability height, adverse side effect minimizing; Its preparation method is comparatively simple, and is convenient.
Claims (7)
1. mifepristone preparation, basically by mifepristone and pharmaceutically acceptable surfactant, and the medical additive composition, described pharmaceutically acceptable surfactant is selected from the surfactant and the ionic surfactant of nonionic or has nonionic surfactant concurrently and the material of ionic surfactant; The amount ratio of mifepristone and ionic surfactant is 1: 0.05-1: 5 by weight; The amount ratio of mifepristone and nonionic surfactant is 1: 0.5-1: 20 by weight.
2. mifepristone preparation according to claim 1, wherein said nonionic surfactant is selected from Macrogol 2000-20000 and molecular weight is 1000-9900, and the content of oxireme is the pharmaceutically acceptable nonionic surfactant of the polyox-yethylene-polyoxypropylene block copolymer of 10-90wt%.
3. mifepristone preparation according to claim 1, wherein said ionic surfactant are selected from the pharmaceutically acceptable ionic surfactant of sodium lauryl sulphate, sodium cholate, eight sodium alkyl sulfonates and bromo geramine.
4. mifepristone preparation according to claim 2, wherein surfactant is a Macrogol 4000, wherein, the weight ratio of mifepristone and Macrogol 4000 is 1: 1-1: 5.
5. mifepristone preparation according to claim 3, wherein surfactant is a sodium lauryl sulphate, wherein, the weight ratio of mifepristone and sodium lauryl sulphate is 1: 0.1-1: 1.5.
6. method for preparing mifepristone preparation as claimed in claim 1 comprises:
A). make the solid dispersion of mifepristone by following three kinds of methods:
Be 1 with pharmaceutically acceptable nonionic surfactant with weight ratio with mifepristone ⅰ): 0.5-1: 20 amount is mixed, heating and melting; Or
Be 1 with pharmaceutically acceptable nonionic surfactant with weight ratio with mifepristone ⅱ): 0.5-1: 20 amount is mixed back solubilizer dissolving, and evaporating solvent is to doing; Or
Be 1 with pharmaceutically acceptable nonionic surfactant with weight ratio with mifepristone ⅲ): 0.5-1: 20 amount is mixed, is ground to and melts;
Perhaps
B). with weight ratio is 1: 0.05-1: 5 measure the ethanol that mifepristone and pharmaceutically acceptable ionic surfactant are dissolved in meltage; And
C). when needing, steps A) and/or step B) material that makes mixes with medical additive, granulate with the method for routine.
7. the application of mifepristone preparation according to claim 1 in the medicine of gynaecopathias such as preparation antiearly pregnancy miscarriage medicine, emergency contraception and treatment hysteromyoma, endometriosis, breast carcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97126039 CN1218665A (en) | 1997-12-03 | 1997-12-03 | High efficiency mifepristone preparation and its preparing method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97126039 CN1218665A (en) | 1997-12-03 | 1997-12-03 | High efficiency mifepristone preparation and its preparing method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1218665A true CN1218665A (en) | 1999-06-09 |
Family
ID=5177519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97126039 Pending CN1218665A (en) | 1997-12-03 | 1997-12-03 | High efficiency mifepristone preparation and its preparing method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1218665A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022067A1 (en) * | 2002-09-05 | 2004-03-18 | Shanghai Institute Of Pharmaceutical Industry | Semi-solid skeleton composition of mifepristone |
| FR2850022A1 (en) * | 2003-01-22 | 2004-07-23 | Centre Nat Rech Scient | Modulating the hedgehog protein signaling pathway, e.g. for treatment of tumors, neurodegenerative diseases or diabetes, using mifepristone or related steroid or D-homo-steroid compounds |
| WO2006133194A3 (en) * | 2005-06-06 | 2007-06-07 | Vgx Pharmaceuticals Inc | Methods for treating viral infection with oral or injectible drug solution |
| EP1990044A1 (en) | 2007-04-30 | 2008-11-12 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
| CN102106805B (en) * | 2009-12-29 | 2013-06-12 | 上海中西制药有限公司 | Cymipristone solid preparation and preparation method thereof |
| CN103932998A (en) * | 2014-02-27 | 2014-07-23 | 范开华 | Orally disintegrating tablet of dry mifepristone emulsion, and preparation method thereof |
| CN114376990A (en) * | 2022-01-21 | 2022-04-22 | 深圳市资福药业有限公司 | Mifepristone capsule and preparation method thereof |
-
1997
- 1997-12-03 CN CN 97126039 patent/CN1218665A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022067A1 (en) * | 2002-09-05 | 2004-03-18 | Shanghai Institute Of Pharmaceutical Industry | Semi-solid skeleton composition of mifepristone |
| FR2850022A1 (en) * | 2003-01-22 | 2004-07-23 | Centre Nat Rech Scient | Modulating the hedgehog protein signaling pathway, e.g. for treatment of tumors, neurodegenerative diseases or diabetes, using mifepristone or related steroid or D-homo-steroid compounds |
| WO2006133194A3 (en) * | 2005-06-06 | 2007-06-07 | Vgx Pharmaceuticals Inc | Methods for treating viral infection with oral or injectible drug solution |
| EP1990044A1 (en) | 2007-04-30 | 2008-11-12 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
| CN102106805B (en) * | 2009-12-29 | 2013-06-12 | 上海中西制药有限公司 | Cymipristone solid preparation and preparation method thereof |
| CN103932998A (en) * | 2014-02-27 | 2014-07-23 | 范开华 | Orally disintegrating tablet of dry mifepristone emulsion, and preparation method thereof |
| CN103932998B (en) * | 2014-02-27 | 2016-03-30 | 范开华 | A kind of mifepristone does newborn oral cavity disintegration tablet and preparation method thereof |
| CN114376990A (en) * | 2022-01-21 | 2022-04-22 | 深圳市资福药业有限公司 | Mifepristone capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1039086C (en) | Low dose dry pharmaceutical preparations | |
| EP1844765B1 (en) | Slow release estradiol-progesterone formulation | |
| CN1163103A (en) | Controlled releasing of steroid from sugarcoating | |
| CN1210079C (en) | Medicine for vaginal ring and its application | |
| CN1104487A (en) | drug granules | |
| CN1141168A (en) | Controlled release of steroids from sugar coattings | |
| CN1148224C (en) | Cyclosporin containing composition and process for preparation | |
| CN1107157A (en) | Methods for the treatment of peri-menopausal syndrome | |
| AU2002350082B9 (en) | Process for preparing quick dissolving, high loading ribavirin compositions | |
| CN1107156A (en) | Methods of inhibiting uterine fiberosis | |
| CN1132478A (en) | A novel pharmaceutical for oral administration comprising progresterone and a polyethyelene glycol together with an exipient | |
| EP1990044A1 (en) | Mifepristone pharmaceutical compositions and their methods of preparation | |
| CN1218665A (en) | High efficiency mifepristone preparation and its preparing method and use | |
| CN1138547C (en) | Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies | |
| CN1819820A (en) | Pharmaceutical formulation comprising levothyroxine sodium | |
| CN1108091A (en) | Methods of inhibiting fertility in women | |
| CN1382053A (en) | Novel hormonal composition and use thereof | |
| CN1377264A (en) | A method of treating endometriosis or infertility or enhancing fertility | |
| RU2269342C9 (en) | Pharmaceutical combination of ethynylestradiol and drospirenone for using as contraceptive | |
| CN101732235B (en) | Method for preparing solid dispersion of tamoxifen citrate | |
| WO2008101375A1 (en) | A gastric retentive sustained-release pharmaceutical composition comprising irbesartan | |
| CN100335058C (en) | Composition and tablet of mifepristone and anorethidrane dipropionate | |
| CN1692909A (en) | Dosmalfate dispersion tablet and its prepn. method | |
| CN1245163C (en) | Puerarin dispersing tablet composition and its preparation method | |
| CN1165311C (en) | Slow-releasing composition of estrogen medicine and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |